Barclays PLC restated their equal weight rating on shares of Bristol-Myers Squibb Co. (NYSE:BMY) in a research report sent to investors on Wednesday morning.

Other equities research analysts also recently issued research reports about the stock. Goldman Sachs Group Inc. reaffirmed a buy rating on shares of Bristol-Myers Squibb in a research note on Wednesday, July 6th. Citigroup Inc. dropped their price target on shares of Bristol-Myers Squibb from $80.00 to $75.00 and set a buy rating on the stock in a research note on Wednesday, August 3rd. Leerink Swann reaffirmed a buy rating and set a $85.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, July 29th. Vetr raised shares of Bristol-Myers Squibb from a sell rating to a buy rating and set a $78.73 price target on the stock in a research note on Monday, July 25th. Finally, Zacks Investment Research raised shares of Bristol-Myers Squibb from a hold rating to a buy rating and set a $85.00 price target on the stock in a research note on Wednesday, July 13th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $69.31.

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Shares of Bristol-Myers Squibb (NYSE:BMY) traded up 0.2002% during midday trading on Wednesday, hitting $50.1101. 5,959,834 shares of the stock traded hands. The stock has a market cap of $83.73 billion, a price-to-earnings ratio of 29.3042 and a beta of 0.74. Bristol-Myers Squibb has a one year low of $49.12 and a one year high of $77.12. The firm has a 50-day moving average price of $55.58 and a 200 day moving average price of $66.51.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The business had revenue of $4.90 billion for the quarter, compared to analyst estimates of $4.60 billion. Bristol-Myers Squibb had a net margin of 16.63% and a return on equity of 24.92%. The business’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.53 EPS. Analysts anticipate that Bristol-Myers Squibb will post $2.63 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 1st. Investors of record on Friday, October 7th will be issued a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a dividend yield of 3.04%. The ex-dividend date is Wednesday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 87.36%.

In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 23,200 shares of the stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $59.17, for a total value of $1,372,744.00. Following the completion of the sale, the director now directly owns 364,999 shares of the company’s stock, valued at approximately $21,596,990.83. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.24% of the company’s stock.

A number of hedge funds have recently modified their holdings of BMY. MSI Financial Services Inc increased its stake in shares of Bristol-Myers Squibb by 4.9% in the third quarter. MSI Financial Services Inc now owns 155,706 shares of the biopharmaceutical company’s stock worth $8,395,000 after buying an additional 7,305 shares during the period. Gulf International Bank UK Ltd increased its stake in shares of Bristol-Myers Squibb by 0.8% in the third quarter. Gulf International Bank UK Ltd now owns 507,590 shares of the biopharmaceutical company’s stock worth $27,369,000 after buying an additional 3,950 shares during the period. First PREMIER Bank increased its stake in shares of Bristol-Myers Squibb by 3.6% in the third quarter. First PREMIER Bank now owns 5,818 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 200 shares during the period. AT Bancorp increased its stake in shares of Bristol-Myers Squibb by 7.8% in the third quarter. AT Bancorp now owns 8,374 shares of the biopharmaceutical company’s stock worth $452,000 after buying an additional 609 shares during the period. Finally, Edge Wealth Management LLC increased its stake in shares of Bristol-Myers Squibb by 620.5% in the third quarter. Edge Wealth Management LLC now owns 6,953 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 5,988 shares during the period. 72.88% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Receive News & Stock Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related stocks with our FREE daily email newsletter.